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Mutations in the RP2 Gene Cause Disease in 10% of
Families with Familial X-Linked Retinitis Pigmentosa
Assessed in This Study
To the Editor:
X-linked retinitis pigmentosa (XLRP; MIM 312600) is
a severe form of retinal degeneration that typically pre-
sents as loss of the peripheral visual field and night blind-
ness in affected males within the 1st or 2d decade of life,
owing to primary degeneration of rod photoreceptor
cells and bone spicule pigmentary deposits (Bird 1975).
The disease is progressive: loss of central vision occurs
later in life, and complete functional blindness often oc-
curs by 40–50 years of age. RP2 was the first genetically
mapped retinitis pigmentosa (RP) locus (Bhattacharya
et al. 1984) and showed disease segregation with the
RFLP detected by the probe L1.28 (DXS7). Subsequent
genetic-mapping studies have shown exceptional genetic
heterogeneity for autosomal RP and XLRP, which is
illustrated on the short arm of the X chromosome
and on RP2, RP3, RP15, and RP23 (Ott et al. 1990;
McGuire et al. 1995; Thiselton et al. 1996; A. J. Hard-
castle, D. L. Thiselton, T. S. Mah, M. B. Gorin, and
S. S. Bhattacharya, unpublished data). Extensive ho-
mogeneity and heterogeneity analyses of worldwide
XLRP family collections suggested that RP3 (frequency
70%–75%) and RP2 (frequency 20%–25%) are the pre-
dominant forms (Ott et al. 1990; Teague et al. 1994).
The RP3 gene was positionally cloned, facilitated by the
identification of submicroscopic deletions in affected pa-
tients (Meindl et al. 1996; Roepman et al. 1996). The
causative gene, a putative guanine-nucleotide-exchange
factor (RPGR), appears to be mutated in only 15%–
20% of patients with XLRP (Meindl et al. 1996; Roep-
man et al. 1996; Buraczynska et al. 1997), not the
70%–75% expected from the results of genetic-mapping
studies (Teague et al. 1994). Investigation of splice var-
iants, promoter/enhancer mutations, and as yet uniden-
tified exons may account for the low mutation rate de-
tected in this gene; however, a more likely explanation
for these findings is microheterogeneity. In comparison,
genetic mapping suggested that RP2 is rare (15%–20%
of patients with XLRP), and the close proximity to RP3,
together with a lack of disease-associated deletions, has
hampered the search for the RP2 gene for many years.
We reported haplotype analysis for two pedigrees, which
defined both proximal and distal boundaries of the RP2
critical interval to a region of 5 cM between DXS8083
(Xp11.3) and DXS6616 (Xp11.23) (Thiselton et al.
1996) and which excluded the candidate gene TIMP1
(Hardcastle et al. 1997b). The RP2 gene recently has
been positionally cloned by targeting this interval by use
of the YAC representation hybridization technique
(Schwahn et al. 1998). RP2 consists of five exons,
encodes a polypeptide of 350 amino acids, and is
ubiquitously expressed. The predicted amino acid se-
quence has homology to cofactor C, over 151 amino
acids (30.4%), which is involved in b-tubulin folding
(Schwahn et al. 1998). Currently, this provides the only
functional clue for the RP2 gene; hence, the overall func-
tion and specific role in the retina are unknown at pres-
ent. We have screened our panel of patients with XLRP
for mutations in the RP2 gene, to define the spectrum
of mutations causing disease. Of particular interest were
the two definitive genetically defined families with RP2
that we had described previously (families F72 andNRP;
Thiselton et al. 1996).
Appropriate informed consent was obtained from pa-
tients and relatives. Of a total of 59 families with XLRP
assessed in this study, 26 families were excluded from
RP2 gene mutation screening, because haplotype and
linkage analyses excluded the RP2 interval or because
RPGR mutations had already been identified. The re-
maining 33 families with XLRP were assessed for RP2
mutations.
DNA from affected male patients from each of the 33
pedigrees (and two normal male controls) was amplified
with primer pairs described by Schwahn et al. (1998),
by use of 150 ng of initial template DNA and withminor
modifications to the suggested annealing temperatures
(details available on request from the authors). Purified
PCR products (8 ml of product incubated with 1 U
shrimp alkaline phosphatase [SAP; Amersham Life Sci-
ence] and 1 U Exonuclease I [United States Biochemical]
in SAP buffer, at 37C for 30 min followed by 80C for
15 min) were aliquoted (5 ml) for cycle sequencing in
the forward and reverse directions, by use of the ABI
Prism Ready Reaction Dye Terminator cycle sequencing
kit (fluorescent sequencing kit, Perkin-Elmer), in accor-
dance with the manufacturer’s instructions. Reactions
then were electrophoresed on an ABI 373A automated
sequencer.
Segregation of the mutation, with the disease, was
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Figure 1 cDNA and predicted amino acid sequence of the RP2 gene
shown by SSCP analysis. PCR products were labeled by
incorporation of a[32P]-dCTP during amplification. De-
natured PCR products were resolved by SSCP analysis
(Orita et al. 1989), in nondenaturing 0.5# mutation-
detection–electrophoresis gels (FMC Bioproducts) in
0.6# Tris-borate EDTA buffer run at 8–10W for 14–18
h. Autoradiographs were exposed at 80C for 1–12 h.
In addition, DNA from 50 female controls (100 chro-
mosomes) was amplified, together with DNA from a
patient harboring each mutation found, and was sepa-
rated under the same conditions.
To complete an effective mutation screen at the se-
quence level, the wild-type RP2 gene sequence was com-
piled by complete sequencing of DNA from two unaf-
fected males (see above) and by cloning of the cDNA,
because no DNA sequence information was publicly
available. Human brain cDNA (∼150 ng, from Dr. M.
Cheetham) was amplified by use of the 1F/5R primers
described by Schwahn et al. (1998). PCR was performed
by use of proofreading Taq polymerase (KlenTaq, Clon-
tech), with an initial denaturation at 94C for 3 min
followed by 40 cycles of 94C for 20 s, 57C for 20 s,
and 68C for 1 min 30 s. The resultant product was
cloned directly into pGEM-T Easy (Promega) in accor-
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Figure 2 Electropherograms depicting mutations in patients with XLRP and normal sequences in the RP2 gene. A, 5-bp deletion in exon
2 (del688–692) in affected male from family NRP. B, Normal sequence of corresponding region in exon 2. C, 1-bp insertion (T) in exon 4
(929insT) in affected male from family RP3877. D, Normal sequence of corresponding region in exon 4. E, Nonsense mutation in exon 2
(C358T) in affected male from family F15. F, Normal sequence of corresponding region in exon 2. G, Missense mutation in exon 2 (G353A)
in affected male from family F72. F, Normal sequence of corresponding region in exon 2.
dance with the manufacturer’s instructions. DNA was
prepared from 1F/5R PCR-positive colonies (QIAprep
Spin Miniprep kit, Quiagen) and was sequenced bidirec-
tionally on the ABI sequencer, by use of the vector and
internal primers described by Schwahn et al. (1998). The
cDNA sequence for the RP2 gene is shown in figure 1,
along with the predicted amino acid sequence. The
amino acid sequence deviates from the published se-
quence by one residue (residue 169; Asp[D]rAsn[N]).
Sequence information from all patients, covering the en-
tire coding region and the exon/intron boundaries, was
examined for mutations by use of Sequence Navigator
software (Perkin Elmer), to compile normal and patient
sequences and to compare them directly to the cloned
RP2 cDNA.
The electropherograms in figure 2 show mutations
found in our patient pool, with normal sequences de-
picted below each mutation sequence. A 5-bp deletion
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Figure 3 SSCP-based cosegregation analysis of two novel RP2
mutations. Pedigree symbols are aligned to correspond to the appro-
priate gel lane. A, Segregation of the exon 2 C358T mutation in family
F71. B, Segregation of the 929insT mutation in family RP3877.
in exon 2 (del688–692) was detected in family NRP, and
the sequence of an affected male from this pedigree is
shown in figure 2A, above the normal sequence of the
gene (fig. 2B). Figure 2C shows the sequence of exon 4
from an affected male in family RP3877. When com-
pared with the normal sequence of the gene in this region
(figure 2D), a 1-bp insertion (T) is apparent (929insT;
see fig. 1), thus causing a frameshift. The most common
mutation observed in our sample set was a nonsense
mutation converting CGA (Arg; fig. 2F) to TGA (ter-
mination codon; fig. 2E) in exon 2 (C358T; see fig. 1),
at a CpG dinucleotide. This mutation was found in three
apparently unrelated pedigrees, namely, F15, F71, and
RP227. One missense mutation was observed in exon 2
in family F72, namely, a CGT (Arg; fig. 2H) to CAT
(His; fig. 2G) change at nucleotide position 353 (G353A;
see fig. 1), which is identical to the missense mutation
reported by Schwahn et al. (1998). In summary, only 6
of the subset of 33 families appeared to harbor muta-
tions in the RP2 gene.
Segregation of mutations, with the disease, was con-
firmed by SSCP analysis, examples of which are seen in
figure 3a (segregation of C358T mutation in family F71)
and in figure 3b (929insT in family RP3877). To rule
out the presence of nonpathogenic sequence variants, all
described mutations were analyzed by SSCP analysis and
were excluded in 50 independent female controls.
Table 1 summarizes the results of our mutation screen
of the subset of 33 pedigrees with XLRP and the mu-
tations described in the original publication (Schwahn
et al. 1998). Of particular interest to us were the two
families we previously had reported as defining the ge-
netic interval for RP2 (families F72 and NRP; Thiselton
et al. 1996). A mutation was identified in exon 2 in an
affected male from family F72; this missense mutation
(G353A, Arg118His) had been reported previously
(Schwahn et al. 1998) and is the only missense mutation
found to date. We also found an RP2 gene mutation in
the second pedigree (NRP). This 5-bp deletion (del688–
692) in exon 2 leads to a premature termination of trans-
lation two amino acids downstream, thus leading to a
severely truncated polypeptide. Further phenotypic stud-
ies of these two families may show slightly differing dis-
ease progression or severity, reflecting the significance of
a subtle point mutation (basic-to-basic amino acid sub-
stitution) and of severe truncation in a protein of un-
known function. One of the original families (F15)
described as showing linkage to the RFLP L1.28 (Bhat-
tacharya et al. 1984) also was included in our sample
subset of 33 pedigrees. In this family, disease segregates
with the nonsense mutation in exon 2 (C358T). The
same mutation was observed in two other families, F71
and RP227, which apparently are unrelated, making this
the most common RP2 mutation to date. A 1-bp in-
sertion in exon 4 (929insT) was identified in pedigree
RP3877. This mutation leads to a frameshift coding for
18 novel amino acids, followed by premature termina-
tion. In summary, from the total set of 59 families with
XLRP assessed in this study, ∼10% (6/59) of cases of
familial disease were caused by mutations in the RP2
gene. When considered together with the original screen,
no mutations in exons 3 and 5 have been detected to
date. The significance of the distribution of mutations
is not known, because the gene is novel; therefore, with-
out an interspecies/gene family sequence with which to
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Table 1
Mutation Spectrum of the RP2 Gene in XLRP
Family/Patient Exon Intron
Nucleotide
Positiona Mutation
10004b 1 Del16–18 Del Ser6
2553b 1 76 Nonsense mutation CAGrTAG, Gln26Stop,
325 aa missing
2967b 1 LINE1 (long interspersed repeated sequence
1) retrotransposition
2613,b F72 2 353 Missense mutation, CGTrCAT, Arg118His
F15, F71, RP227 2 358 Nonsense mutation, CGArTGA,
Arg120Stop, 231 aa missing
1168b 2 453 Nonsense mutation, TACrTAG,
Tyr151Stop, 200 aa missing
3102b 2 Del453 Frameshift, 199 aa missing
NRP 2 Del688–692 Frameshift, 2 aa novel and 117 aa missing
RP3877 4 929 Insertion (T)/frameshift mutation,
GTArGTT, 18 aa novel and 23 aa
missing
2448b 4 Del Frameshift, 55 aa missing
NOTE.—Del  deletion, and aa  amino acids.
a See figure 1.
b Results from the study by Schwahn et al. (1998).
identify conserved residues and domains, functional as-
sessment of pathogenic sequence alterations can only be
speculative.
Interestingly, however, the spectrum of mutations has
a trend toward severe protein truncation, with only one
missense mutation identified in two families (reported
by Schwahn et al. [1998] and F72 in this study). This
suggests a critical role for this residue in protein folding/
function. Because mutations in the RP2 gene that cause
XLRP are skewed toward protein truncation, more
subtle missense mutations may cause a variant pheno-
type such as X-linked congenital stationary night blind-
ness (CSNBX), which also shows genetic heterogeneity
(Hardcastle et al. 1997a). In this study we did not search
for upstream or intronic mutations; however, we do not
anticipate a large increase in the percentage of cases of
XLRP attributable to RP2 gene mutations, since genetic-
mapping studies suggest that a maximum of 25% of
XLRP cases are linked to this interval (Teague et al.
1994).
The only indication of the functional role of this novel
protein in the retina or, indeed, in any tissue is its ho-
mology to cofactor C, which in itself is unique. Cofactor
C was identified as part of the b-tubulin folding pathway
(Tian et al. 1996) and cooperates with the cytosolic
chaperonin (CCT) and other cofactors to produce prop-
erly folded b-tubulin subunits that can form heterodi-
mers with a-tubulin. The precise role of cofactor C is
unknown, but it appears to function as a chaperone late
in this folding pathway, binding near native b-tubulin
(Tian et al. 1996, 1997). Cofactor C also copurifies with
microtubules and also may be a microtubule-associated
protein (MAP). Therefore, RP2 possibly is also a mo-
lecular chaperone involved in tubulin biogenesis or a
specializedMAPmodulating some aspect of microtubule
function. For example, photoreceptors have a specialized
microtubule cilium connecting inner and outer segments,
and RP2 may be involved in either cilium biogenesis or
maintenance. Alternatively, RP2 may act as a chaperone
in cooperation with CCT, by acting to fold proteins other
than b-tubulin, possibly including retina-specific pro-
teins. Studies of the cellular and subcellular localization
of RP2 will provide valuable insights into its physiolog-
ical function and its relationship to other essential retina
proteins (these experiments are currently under way).
The identification of RPGR as the causative gene for
RP3 (Meindl et al. 1996) has not accounted for all the
cases of disease mapped to this genetic interval. Ap-
proximately 20% of families with XLRP have mutations
in this gene (Meindl et al. 1996; Roepman et al. 1996;
Buraczynska et al. 1997), compared with the 75% es-
timated from genetic-mapping studies (Teague et al.
1994), suggesting the potential for microheterogeneity
around this locus. Currently, new XLRP loci are being
identified (RP23; A. J. Hardcastle, D. L. Thiselton, T. S.
Mah, M. B. Gorin, and S. S. Bhattacharya, unpublished
data), suggesting that the level of heterogeneity for this
disease is far greater than originally hypothesized. Be-
cause mutations in the RP2 gene can cause only a max-
imum of 25% of XLRP cases, as determined from
genetic-mapping studies (Teague et al. 1994) and more-
recent mutation studies (Schwahn et al. 1998; this
study), 60% of XLRP cases are still unaccounted for.
The cloning of the RP2 and RP3 genes should facilitate
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disease definition in a significant proportion of XLRP
pedigrees; however, the genetics of XLRP is still complex
and ill defined. The majority of families with XLRP may
have mutations in one or more genes that lie in the
interval between RP2 and RP3, which potentially is al-
lelic with the newly identified location for CSNBX
(CSNB4; Hardcastle et al. 1997a).
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